# Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy

Antonio Di Meglio, Julie Havas, Arnauld S. Gbenou, Elise Martin, Mayssam El-Mouhebb, Barbara Pistilli, Gwenn Menvielle, Agnès Dumas, Sibille Everhard, Anne-Laure Martin, et al.

HAL Id: hal-03855946

https://hal.sorbonne-universite.fr/hal-03855946v1

Submitted on 6 Jun 2023

# Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy

Antonio Di Meglio, MD, PhD[1,2]; Julie Havas, MSc[2]; Arnauld S. Gbenou, MSc[2]; Elise Martin, PhD[2]; Mayssam El-Mouhebb, MSc[2];
Barbara Pistilli, MD[2]; Gwenn Menvielle, PhD[3]; Agnes Dumas, PhD[4]; Sibille Everhard, PhD[5]; Anne-Laure Martin, PhD[5]; Paul H. Cottu, MD[6];
Florence Lerebours, MD[7]; Charles Coutant, MD[8]; Anne Lesur, MD[9]; Olivier Tredan, MD[10]; Patrick Soulie, MD[11];
Laurence Vanlemmens, MD[12]; Florence Joly, MD[13]; Suzette Delaloge, MD[1]; Patricia A. Ganz, MD[14]; Fabrice André, MD, PhD[1,2];
Ann H. Partridge, MD[15]; Lee W. Jones, PhD[16]; Stefan Michiels, PhD[17]; and Ines Vaz-Luis, MD, PhD[1,2]

**PURPOSE** We aimed to characterize long-term quality of life (QOL) trajectories among patients with breast cancer treated with adjuvant chemotherapy and to identify related patterns of health behaviors.

**METHODS** Female stage I-III breast cancer patients receiving chemotherapy in CANTO (CANcer TOxicity; ClinicalTrials.gov identifier: NCT01993498) were included. Trajectories of QOL (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–C30 Summary Score) and associations with trajectory group membership were identified by iterative estimations of group-based trajectory models and multivariable multinomial logistic regression, respectively.

**RESULTS** Four trajectory groups were identified (N = 4,131): excellent (51.7%), very good (31.7%), deteriorating (10.0%), and poor (6.6%) QOL. The deteriorating trajectory group reported fairly good baseline QOL (mean [95% CI], 78.3/100 [76.2 to 80.5]), which significantly worsened at year-1 (58.1/100 [56.4 to 59.9]) and never recovered to pretreatment values through year-4 (61.1/100 [59.0 to 63.3]) postdiagnosis. Healthy behaviors were associated with better performing trajectory groups. Obesity (adjusted odds ratio [aOR] *v* lean, 1.51 [95% CI, 1.28 to 1.79]; $P < .0001$) and current smoking (aOR *v* never, 1.52 [95% CI, 1.27 to 1.82]; $P < .0001$) at diagnosis were associated with membership to the deteriorating group, which was also characterized by a higher prevalence of patients with excess body weight and insufficient physical activity through year-4 and by frequent exposure to tobacco smoking during chemotherapy. Additional factors associated with membership to the deteriorating group included younger age (aOR, 1-year decrement 1.01 [95% CI, 1.01 to 1.02]; $P = .043$), comorbidities (aOR *v* no, 1.22 [95% CI, 1.06 to 1.40]; $P = .005$), lower income (aOR *v* wealthier households, 1.21 [95% CI, 1.07 to 1.37]; $P = .002$), and endocrine therapy (aOR *v* no, 1.14 [95% CI, 1.01 to 1.30]; $P = .047$).

**CONCLUSION** This latent-class analysis identified some patients with upfront poor QOL and a high-risk cluster with severe, persistent postchemotherapy QOL deterioration. Screening relevant patient-level characteristics may inform tailored interventions to mitigate the detrimental impact of chemotherapy and preserve QOL, including early addressal of behavioral concerns and provision of healthy lifestyle support programs.

## INTRODUCTION

Survival of patients with breast cancer (BC) has dramatically increased over the past decades, because of earlier diagnosis and advanced treatment.[1-4] Current multimodal risk-reduction strategies, including adjuvant chemotherapy, endocrine therapies, and targeted agents, lead to survival rates exceeding 80% at 10 years after diagnosis of early-stage BC.[5]

Nevertheless, this survival benefit is often associated with relevant late and long-term health-related costs.[6]

Downstream effects of adjuvant BC treatments include substantial impact on general well-being, physical functioning, and vitality, and alterations in cognition, metabolism, and sexuality.[7-9] Chemotherapy is associated with poorer emotional and social functioning, body-image issues, increased likelihood of unemployment after cancer, and persisting conditions including fatigue, neuropathy, and menopausal symptoms.[10-13]

Previous research indicates an overall transient negative impact of chemotherapy on quality of life (QOL).[6]

## CONTEXT

### Key Objective

There is considerable interindividual variability in long-term trajectories of patient-reported quality of life (QOL) after adjuvant breast cancer chemotherapy. We aimed to identify latent clusters of patients at risk for QOL deterioration, and to assess the relationship of host factors and health behaviors with trajectory group membership.

### Knowledge Generated

Most patients fared well over time; however, a cluster reported significantly worsened QOL after chemotherapy and never recovered to pretreatment values for up to four years after diagnosis. Excess body weight, physical inactivity, and tobacco exposure were particularly prevalent among this deteriorating QOL trajectory group. Additional risk factors for deteriorated QOL included younger age, comorbidities, lower income, and receipt of endocrine therapy.

### Relevance

This study will help identify latent clusters of patients who are at risk of persistent QOL deterioration after chemotherapy and facilitate tailored interventions that may include early addressal of behavioral concerns and provision of healthy lifestyle support programs.

There is, however, considerable interindividual variability in the longitudinal trajectory of patient-reported outcomes (PROs),[14] which may be obscured by a description of the average population level.[15] Few studies comprehensively evaluated PROs beyond the first year after treatment, despite the high prevalence of some symptoms persisting for more than 10 years.[16] Some patient subgroups may follow trajectories at high risk of long-term deterioration in functional health and symptom burden. Data suggest a mediating effect of unhealthy behaviors, such as excess weight, weight gain, and deconditioning, on QOL of post-treatment BC survivors.[17-22] In addition, smokers who continue to do so during cancer treatment have higher odds of severe treatment-related physical or cognitive effects and persistent sleep or mood disturbances.[23-30] Conversely, those who quit are more likely to endure treatments, speed up symptom recovery, and have reduced all-cause mortality.[23,31,32] Frequent alcohol consumption also seems to amplify the risk of adverse health outcomes, including contributing to development of cardiometabolic conditions and obesity.[28,33,34]

Early identification of high-risk groups for QOL deterioration is crucial for timely, patient-specific supportive care interventions, including those facilitating a healthy lifestyle.[35] This study was conducted among women who received adjuvant BC chemotherapy, with the following aims: (1) to describe dynamics of patient-reported QOL over four years after diagnosis of BC; (2) to identify patients at high risk of QOL deterioration; and (3) to focus on how modifiable health behaviors are associated with distinct patterns of QOL over time.

## METHODS

### Data Source

We used data from CANcer TOxicity (CANTO; Clinical-Trials.gov identifier: NCT01993498), a prospective cohort of women enrolled at the time of diagnosis of stage I-II-III BC, before any treatment. Participants are longitudinally assessed at diagnosis (baseline) and during follow-up visits at year-1, -2, and -4 postdiagnosis. Surgery, chemotherapy, and/or radiation therapy are completed 3-6 months before the year-1 visit. Patients experiencing BC recurrence (other than local), second primary cancers, or death provide data until the time of event, and then exit the study (Data Supplement, online only).[36]

### Study Cohort

We included 4,131 patients diagnosed with BC from 2012 to 2015, who received chemotherapy, provided QOL data at diagnosis or during at least one subsequent evaluation, and had potential follow-up reaching year-4 postdiagnosis at the time of analysis (Data Supplement).

### Variables of Interest

**Outcome variables.** Our outcome of interest was the Summary Score of the European Organisation for Research and Treatment of Cancer QOL Questionnaire C30 (range, 0-100). Higher scores indicate better QOL (Data Supplement).[35,37-41]

**Exposure variables.** We focused on behavior-related variables, available at diagnosis and follow-up time points: (1) clinic-assessed body mass index (BMI), categorized as lean ($\leq$ 24.9 kg/m$^2$), overweight (25.0-29.9 kg/m$^2$), or obese ($\geq$ 30.0 kg/m$^2$)[42]; (2) self-reported physical activity (PA; Global Physical Activity Questionnaire-16), with $\geq$ 10 metabolic equivalents of task-hours/week defining sufficiently active (ie, adhering to WHO recommendations) versus insufficiently active patients (< 10)[43]; (3) tobacco use behavior at diagnosis, categorized as current, former, or never smoker; and (4) alcohol consumption behavior at diagnosis, categorized as daily versus less than daily. Tobacco and alcohol behaviors during follow-up were defined as increased or unchanged versus reduced use, compared with the previous assessment.

**TABLE 1.** Distribution of Patient Characteristics at Diagnosis by Quality of Life Trajectory Group (N = 4,131)

| Characteristic | Excellent (n = 2,134; 51.7%) | Very Good (n = 1,312; 31.7%) | Deteriorating (n = 413; 10.0%) | Poor (n = 272; 6.6%) |
|---|---|---|---|---|
| Age, years | | | | |
| Mean (SD) | 54.0 (11.4) | 52.3 (11.3) | 53.1 (9.8) | 52.1 (10.6) |
| Missing | 0 | 0 | 0 | 0 |
| BMI, continuous, kg/m² | | | | |
| Mean (SD) | 25.4 (5.1) | 25.8 (5.4) | 27.1 (5.9) | 26.7 (6.3) |
| Missing | 8 | 3 | 1 | 2 |
| BMI, WHO definition, kg/m² | | | | |
| Lean (≤ 24.9) | 1,175 (55.3) | 679 (51.9) | 181 (43.9) | 124 (45.9) |
| Overweight (25.0-29.9) | 597 (28.1) | 370 (28.3) | 116 (28.2) | 78 (28.9) |
| Obese (≥ 30.0) | 354 (16.7) | 260 (19.9) | 115 (27.9) | 68 (25.2) |
| Missing | 8 | 3 | 1 | 2 |
| Level of PA, continuous, MET-hours/week | | | | |
| Total activity, median (Q1-Q3) | 14.0 (0.0-36.0) | 10.0 (0.0-36.0) | 12.0 (0.0-54.0) | 9.5 (0.0-50.0) |
| Transport and leisure-time activity, median (Q1-Q3) | 10.0 (0.0-24.0) | 6.7 (0.0-20.0) | 4.0 (0.0-18.0) | 0.3 (0.0-18.7) |
| Missing | 106 | 67 | 22 | 14 |
| Level of PA, WHO definition, MET-hours/week | | | | |
| Sufficiently active (≥ 10) | 1,162 (57.3) | 645 (51.8) | 223 (57.0) | 129 (50.0) |
| Insufficiently active (< 10) | 866 (42.7) | 600 (48.2) | 168 (43.0) | 129 (50.0) |
| Missing | 106 | 67 | 22 | 14 |
| Smoking behavior | | | | |
| Current smoker | 339 (16.1) | 260 (20.2) | 107 (26.3) | 96 (35.4) |
| Former smoker | 471 (22.4) | 306 (23.8) | 77 (18.9) | 53 (19.6) |
| Never smoker | 1,295 (61.5) | 721 (56.0) | 223 (54.8) | 122 (45.0) |
| Missing | 29 | 25 | 6 | 1 |
| Alcohol consumption behavior | | | | |
| Less than daily | 1,785 (86.4) | 1,100 (86.4) | 347 (86.8) | 221 (84.0) |
| Daily | 281 (13.6) | 173 (13.6) | 53 (13.2) | 42 (16.0) |
| Missing | 68 | 39 | 13 | 9 |
| Charlson comorbidity score | | | | |
| 0 | 1,661 (84.6) | 956 (79.2) | 286 (76.7) | 173 (73.3) |
| ≥ 1 | 302 (15.4) | 251 (20.8) | 87 (23.3) | 63 (26.7) |
| Missing | 171 | 105 | 40 | 36 |
| Monthly household income, euro | | | | |
| < 3,000 | 1,049 (53.3) | 703 (57.8) | 243 (64.1) | 183 (73.2) |
| ≥ 3,000 | 919 (46.7) | 513 (42.2) | 136 (35.9) | 67 (26.8) |
| Missing | 166 | 96 | 34 | 22 |
| BC stage | | | | |
| I | 564 (26.9) | 332 (25.8) | 96 (23.5) | 60 (22.6) |
| II | 1,184 (56.4) | 720 (55.9) | 239 (58.6) | 150 (56.6) |
| III | 351 (16.7) | 235 (18.3) | 73 (17.9) | 55 (20.8) |
| Missing | 35 | 25 | 5 | 7 |
| BC surgery | | | | |
| Mastectomy | 753 (35.3) | 498 (38.0) | 158 (38.3) | 99 (36.4) |

(continued on following page)

**TABLE 1.** Distribution of Patient Characteristics at Diagnosis by Quality of Life Trajectory Group (N = 4,131) (continued)

| Characteristic | Excellent (n = 2,134; 51.7%) | Very Good (n = 1,312; 31.7%) | Deteriorating (n = 413; 10.0%) | Poor (n = 272; 6.6%) |
|---|---|---|---|---|
| Conservative surgery | 1,381 (64.7) | 814 (62.0) | 255 (61.7) | 173 (63.6) |
| Missing | 0 | 0 | 0 | 0 |
| Axillary surgery | | | | |
| Axillary dissection | 1,191 (55.8) | 775 (59.1) | 259 (62.7) | 171 (62.9) |
| Sentinel node biopsy | 943 (44.2) | 537 (40.9) | 154 (37.3) | 101 (37.1) |
| Missing | 0 | 0 | 0 | 0 |
| Radiation therapy | | | | |
| Yes | 1,990 (93.6) | 1,221 (93.3) | 383 (92.7) | 256 (94.1) |
| No | 137 (6.4) | 88 (6.7) | 30 (7.3) | 16 (5.9) |
| Missing | 7 | 3 | 0 | 0 |
| Endocrine therapy | | | | |
| Yes | 1,564 (73.5) | 992 (75.8) | 325 (78.7) | 201 (73.9) |
| No | 564 (26.5) | 316 (24.2) | 88 (21.3) | 71 (26.1) |
| Missing | 6 | 4 | 0 | 0 |
| Anti-HER2 therapy | | | | |
| Yes | 477 (22.4) | 296 (22.6) | 87 (21.1) | 57 (21.0) |
| No | 1,654 (77.6) | 1,015 (77.4) | 326 (78.9) | 215 (79.0) |
| Missing | 3 | 1 | 0 | 0 |

NOTE. Data are No. (%) unless otherwise indicated.

Abbreviations: BC, breast cancer; BMI, body mass index; HER2, human epidermal growth factor receptor 2; MET, metabolic equivalent of task; PA, physical activity; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.

**Covariates.** These included clinical, socioeconomic, tumor, and treatment characteristics collected at diagnosis (Table 1).

### Statistical Analysis

**Cohort description.** Patient characteristics were descriptively summarized.

**Definition of trajectory groups.** Longitudinal variations in C30 Summary Score were assessed by Group-Based Trajectory Modeling (GBTM).[44-48] This procedure allowed to define polynomial trajectories and to identify unobserved clusters (latent trajectory groups) of individuals following a similar outcome course. Model selection involved the iterative estimation of the best-fitting (1) number of trajectory groups and (2) shape/order of each trajectory group, tested using maximum likelihood methods. In estimating trajectory groups, time was categorized into years. A detailed description of the model selection procedure is provided in the Data Supplement.

Each identified trajectory group was assigned a label name to provide a brief descriptive representation for the associated QOL outcome pattern. After latent-group identification, we described participant characteristics in each group.

Mean scores for all scales included in the European Organisation for Research and Treatment of Cancer QOL Questionnaire C-30 were summarized by trajectory group, to (1) complement the information provided by the C30 Summary Score, and (2) provide additional granular details on the dynamics of its distinct components.

**Trajectory group membership.** A weighted multivariable multinomial logistic regression model was subsequently fit to estimate associations between baseline covariates and trajectory group membership. The best pattern of the C30 Summary Score was chosen as reference, in order to focus on factors associated with clustering into groups with worse patterns. To manage missing covariate data, 30 complete-data replicates were obtained using Multivariate Imputation by Chained Equations.[49] The imputation model included all covariates that were part of the analytic model, as well as the outcome and predefined auxiliary variables. The multinomial logistic regression analysis was then applied to each individual imputed data set, and results were combined using Rubin's rules to produce estimates and CIs that incorporate uncertainty of imputed values.[50]

**Health behaviors and trajectory groups.** Longitudinal measures of BMI, body weight, PA, tobacco, and alcohol behavior were then tabulated and described by trajectory group.

**Sensitivity analyses.** An extension of GBTM was used to address potential nonrandom participant dropout (eg, truncation because of BC recurrence, second cancer, or death events) that may vary across groups (Data Supplement,

Sensitivity Analysis 1).[51] In addition, analyses were repeated in the overall cohort (n = 4,863, Data Supplement), regardless of a potential follow-up reaching year-4 post-diagnosis (Sensitivity Analysis 2).

Analyses were performed using SAS, v9.4 (including the PROC TRAJ) and R, v4.0.3 (MICE package). Statistical significance was defined with a $P < .05$.

## RESULTS

### Cohort Characteristics

In the whole cohort (N = 4,131), the mean age was 53.2 years (standard deviation 11.2), 1,161 (28.2%) and 797 (19.4%) patients were overweight and obese, respectively, 1,763 (45.0%) were insufficiently active, 802 (19.7%) current smokers, and 549 (13.3%) consumed alcohol daily (Data Supplement).

### QOL Trajectory Groups

Our final model identified four trajectory groups (Fig 1). Model selection metrics are presented in the Data

Supplement. The best trajectory group comprised the majority of patients (n = 2,134, 51.7%; excellent), reporting an excellent overtime pattern of C30 Summary Score. The second trajectory group (n = 1,312, 31.7%; very good) fared very well overall, with transient and unremarkable downward inflections in QOL scores at year-1 and year-2. QOL in the third trajectory group (n = 413, 10.0%; deteriorating) was fairly good at diagnosis, with a mean score of 78.3/100 (95% CI, 76.2 to 80.5), similar to the second group, but then declined significantly at 58.1/100 (95% CI, 56.4 to 59.9) at year-1, and recovered only partially at 61.1 (95% CI, 59.0 to 63.3) by year-4. The fourth group (n = 272, 6.6%; poor) reported overall low/very low scores averaging 54.7/100 (53.0 to 56.4) at diagnosis, with some additional downward inflections, then slowly and only partially recovering until year-4.

The deteriorating trajectory group reported mean values crossing the threshold for clinically important functional impairment or symptom severity[52] across multiple QOL domains and experienced the largest mean score changes from diagnosis to year-1 (ie, segment including the chemotherapy treatment portion), showing the greatest



| No. (%) of patients |
|---|
| 2,134 (51.7) — Excellent |
| 1,312 (31.7) — Very good |
| 413 (10.0) — Deteriorating |
| 272 (6.6) — Poor |

C30 Summary Score Values and Respective 95% CIs by Trajectory-Group (N = 4,131)

| Trajectory Group | Assigned Patients | Mean Value | 95% CI | | Mean Value | 95% CI | | Mean Value | 95% CI | | Mean Value | 95% CI | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | Lower | Upper | | Lower | Upper | | Lower | Upper | | Lower | Upper |
| | No. (%) | Diagnosis | | | Year-1 | | | Year-2 | | | Year-4 | | |
| Excellent | 2,134 (51.7) | 88.8 | 88.1 | 89.5 | 87.6 | 87.0 | 88.3 | 87.6 | 86.9 | 88.3 | 88.6 | 87.8 | 89.5 |
| Very good | 1,312 (31.7) | 76.9 | 75.8 | 78.0 | 74.5 | 73.5 | 75.5 | 74.4 | 73.3 | 75.4 | 76.4 | 75.2 | 77.6 |
| Deteriorating | 413 (10.0) | 78.3 | 76.2 | 80.5 | 58.1 | 56.4 | 59.9 | 61.0 | 59.1 | 63.0 | 61.1 | 59.0 | 63.3 |
| Poor | 272 (6.6) | 54.7 | 53.0 | 56.4 | 48.3 | 46.9 | 49.7 | 48.0 | 46.3 | 49.7 | 53.9 | 51.2 | 56.5 |

**FIG 1.** Trajectory groups according to best-fitting model (N = 4131). Solid lines represent the predicted trajectories and dashed lines represent the respective 95% CIs. The table below the figure displays the predicted C30 Summary Score values and respective 95% CIs by trajectory group. C30 Summary Scores were available for 3,816 patients at diagnosis, and then among 3,477 at year-1 follow-up; 3,102 at year-2 follow-up; and 2,241 patients at year-4 follow-up. Higher scores reflect better QOL. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; QOL, quality of life.

**FIG 2.** (A) Mean QOL scores by trajectory group and by time point: EORTC QLQ-C30 functions; (B) mean QOL scores by trajectory group and by time point: EORTC QLQ-C30 symptoms. Thresholds for clinical importance are defined by horizontal, dotted gray lines. Higher scores indicate greater functionality and symptomatology. Scores below and above the threshold indicate clinically important functional impairment and symptomatology, respectively (Giesinger JM, et al: *J Clin Epidemiol* 2020). Respective 95% CIs for the means are available in the Data Supplement. EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; QOL, quality of life. (continued on following page)

impairment across the four trajectory groups (Figs 2A and 2B, red trajectory lines; Data Supplement).

**Trajectory Group Membership**

Table 1 displays patient characteristics by trajectory group.

Compared with the excellent group, there were consistent associations of membership to the very good, deteriorating, and poor trajectory groups for women with obesity at diagnosis (odds ratio [OR] *v* lean [95% CI]: 1.13 [1.00 to 1.28], 1.51 [1.28 to 1.79], and 1.34 [1.08 to 1.65],

**FIG 2.** (Continued)

respectively). Current smoker status was also consistently associated with group membership to the deteriorating and poor trajectory groups (ORs v never smoker [95% CI], 1.52 [1.27 to 1.82] and 1.82 [1.49 to 2.22], respectively). There were no significant associations between alcohol behavior and group membership. In addition, younger women (adjusted OR for a 1-year decrement [95% CI]: 1.02 [1.01 to 1.02], 1.01 [1.01 to 1.02], and 1.02 [1.01 to 1.03],

respectively), those with comorbidities (adjusted OR v no [95% CI], 1.19 [1.08 to 1.31], 1.22 [1.06 to 1.40], and 1.36 [1.15 to 1.60], respectively), and those with lower monthly income (OR v women living in wealthier households [95% CI], 1.11 [1.03 to 1.20], 1.21 [1.07 to 1.37], and 1.44 [1.23 to 1.69], respectively) more likely belonged to trajectory groups with very good, deteriorating, and poor QOL patterns compared with excellent patterns, respectively. Receipt of endocrine therapy was significantly associated with increased likelihood of membership to the deteriorating group (OR v no [95% CI], 1.14 [1.01 to 1.30]; Table 2).

## Health Behaviors and Trajectory Groups

Overall, the proportion of overweight or obese patients was highest among deteriorating and poor groups at diagnosis (56.1% and 54.1%, respectively) and remained highest at year-4 (60.5% and 61.7%, respectively). Some small reductions in weight were observed among patients with obesity in groups at better QOL. There were also differential patterns in PA participation. In the excellent and very good QOL groups, fewer patients at year-4 reported being insufficiently active (not reaching 10 metabolic equivalents of task-hours/week of activity) respective to diagnosis (42.7% at diagnosis and 36.4% at year-4 in the former group and 48.2% at diagnosis and 37.6% at year-4 in the latter group). Conversely, PA was relatively high in the deteriorating group at diagnosis; however, it seemed to decrease

through year-4, with a proportion of insufficiently active patients of 42.9% at diagnosis and 46.3% at year-4. The poor group had overall higher rates of insufficient PA participation. In addition, in the deteriorating and poor QOL groups, the prevalence of current smokers at diagnosis was highest (26.3% and 35.4%, respectively), and most of them persisted smoking during chemotherapy (63.7% and 67.1% at year-1, respectively) (Table 3).

## Sensitivity Analyses

The results of sensitivity analyses were consistent with main findings. Particularly, number of groups and factors associated with group membership were confirmed in analyses accounting for potential nonrandom dropout and in an expanded analytic cohort (Data Supplement).

## DISCUSSION

Using a latent-class analysis, we identified four different trajectories among breast cancer survivors receiving chemotherapy, characterized by excellent (51.7%), very good (31.7%), deteriorating (10.0%), and poor (6.6%) patient-reported QOL patterns. Women clustered in the deteriorating group had significantly worsened QOL following chemotherapy and never recovered to pretreatment values. Excess body weight, reduced PA, and tobacco exposure were frequent among the deteriorating

**TABLE 2.** Multinomial Logistic Regression of Factors Associated With C30 Summary Score Trajectory Group Membership (v reference Excellent, No. = 2,134 [51.7%])

| Factor | Very Good (n = 1,312; 31.7%) | | Deteriorating (n = 413; 10.0%) | | Poor (n = 272; 6.6%) | |
|---|---|---|---|---|---|---|
| | aOR[a] (95% CI) | P | aOR[a] (95% CI) | P | aOR[a] (95% CI) | P |
| Age, continuous (1-year decrement) | 1.02 (1.01 to 1.02) | < .0001 | 1.01 (1.01 to 1.02) | .043 | 1.02 (1.01 to 1.03) | < .001 |
| BMI, overweight v lean | 0.99 (0.89 to 1.11) | .886 | 0.93 (0.79 to 1.10) | .393 | 0.99 (0.81 to 1.20) | .902 |
| BMI, obese v lean | 1.13 (1.00 to 1.28) | .052 | 1.51 (1.28 to 1.79) | < .0001 | 1.34 (1.08 to 1.65) | .007 |
| PA, sufficiently v insufficiently active | 0.91 (0.84 to 0.97) | .008 | 1.04 (0.93 to 1.17) | .469 | 0.89 (0.78 to 1.02) | .097 |
| Smoking behavior, current v never smoker | 1.13 (0.99 to 1.28) | .062 | 1.52 (1.27 to 1.82) | < .0001 | 1.82 (1.49 to 2.22) | < .0001 |
| Smoking behavior, former v never smoker | 1.01 (0.90 to 1.13) | .894 | 0.79 (0.65 to 0.95) | .011 | 0.80 (0.65 to 1.00) | .050 |
| Alcohol behavior, daily v less than daily | 1.02 (0.92 to 1.14) | .683 | 0.99 (0.84 to 1.17) | .922 | 1.11 (0.92 to 1.33) | .281 |
| Charlson comorbidity index score, ≥ 1 v 0 | 1.19 (1.08 to 1.31) | < .001 | 1.22 (1.06 to 1.40) | .005 | 1.36 (1.15 to 1.60) | < .001 |
| Marital status, partnered v not | 1.06 (0.96 to 1.16) | .276 | 1.08 (0.93 to 1.25) | .308 | 0.96 (0.82 to 1.13) | .659 |
| Income, < 3,000 v ≥ 3,000 euro/month | 1.11 (1.03 to 1.20) | .010 | 1.21 (1.07 to 1.37) | .002 | 1.44 (1.23 to 1.69) | < .0001 |
| BC stage, II v I | 0.97 (0.88 to 1.07) | .519 | 1.03 (0.89 to 1.19) | .703 | 0.95 (0.80 to 1.14) | .582 |
| BC stage, III v I | 1.00 (0.87 to 1.16) | .988 | 0.93 (0.75 to 1.16) | .539 | 1.10 (0.85 to 1.43) | .457 |
| BC surgery, mastectomy v partial | 1.02 (0.94 to 1.11) | .579 | 1.01 (0.89 to 1.15) | .860 | 0.95 (0.81 to 1.10) | .476 |
| Axillary surgery, dissection v sentinel node biopsy | 1.05 (0.96 to 1.15) | .267 | 1.14 (0.99 to 1.30) | .060 | 1.12 (0.95 to 1.33) | .162 |
| Radiation therapy, yes v no | 0.98 (0.85 to 1.14) | .820 | 0.93 (0.74 to 1.16) | .495 | 1.00 (0.75 to 1.33) | .990 |
| Endocrine therapy, yes v no | 1.05 (0.97 to 1.14) | .195 | 1.14 (1.01 to 1.30) | .047 | 0.99 (0.85 to 1.14) | .860 |
| Anti-HER2 therapy, yes v no | 1.01 (0.93 to 1.10) | .838 | 0.99 (0.87 to 1.13) | .857 | 0.98 (0.84 to 1.15) | .823 |

Abbreviations: aOR, adjusted odds ratio; BC, breast cancer; BMI, body mass index; HER2, human epidermal growth factor receptor 2; PA, physical activity.
[a]Models are adjusted for all the factors in the table.

**TABLE 3.** Distribution of Health Behaviors by Quality of Life Trajectory Group in the Whole Cohort (N = 4,131)

| Health Behavior | Excellent (n = 2,134; 51.7%) | Very Good (n = 1,312; 31.7%) | Deteriorating (n = 413; 10.0%) | Poor (n = 272; 6.6%) |
|---|---|---|---|---|
| BMI, continuous, mean (SD), kg/m² | | | | |
| Diagnosis | 25.4 (5.1) | 25.8 (5.4) | 27.1 (5.9) | 26.7 (6.3) |
| Year-1 | 25.5 (5.1) | 25.9 (5.4) | 27.1 (6.0) | 26.7 (6.9) |
| Year-2 | 25.8 (5.2) | 26.2 (5.3) | 27.7 (6.0) | 27.4 (6.8) |
| Year-4 | 25.7 (4.9) | 26.1 (5.2) | 27.4 (6.0) | 27.8 (6.8) |
| Overweight or obese, % | | | | |
| Diagnosis | 44.7 | 48.1 | 56.1 | 54.1 |
| Year-1 | 46.6 | 49.4 | 57.6 | 50.0 |
| Year-2 | 48.0 | 51.1 | 60.3 | 55.6 |
| Year-4 | 49.6 | 51.7 | 60.5 | 61.7 |
| Mean weight change, kg (95% CI) compared with diagnosis | | | | |
| Among obese at diagnosis | n = 354 (16.7%) | n = 260 (19.9%) | n = 115 (27.9%) | n = 68 (25.2%) |
| Year-1 | −1.00 (−1.67 to −0.33) | −1.37 (−2.11 to −0.62) | −0.49 (−1.61 to +0.63) | +1.53 (−0.11 to +3.17) |
| Year-2 | −0.07 (−0.89 to +0.75) | −0.76 (−1.69 to +0.17) | +0.70 (−0.55 to +1.96) | +2.17 (+0.29 to +4.05) |
| Year-4 | −0.91 (−1.83 to +0.01) | −2.67 (−4.16 to −1.19) | +0.34 (−1.34 to +2.01) | +0.40 (−2.50 to +3.30) |
| Lost at least 5% of weight compared with diagnosis, % | | | | |
| Among obese at diagnosis[a] | n = 354 (16.7%) | n = 260 (19.9%) | n = 115 (27.9%) | n = 68 (25.2%) |
| Year-1 | 27.6 (88/319) | 25.8 (61/236) | 21.1 (23/109) | 14.7 (9/61) |
| Year-2 | 23.4 (68/290) | 25.8 (57/221) | 20.2 (21/104) | 11.1 (6/54) |
| Year-4 | 28.8 (67/233) | 32.2 (56/174) | 23.5 (19/81) | 26.7 (12/45) |
| Level of PA, continuous, MET-hours/week | | | | |
| Total activity, median (Q1-Q3) | | | | |
| Diagnosis | 14.0 (0.0-36.0) | 10.0 (0.0-36.0) | 12.0 (0.0-54.0) | 9.5 (0.0-50.0) |
| Total activity, absolute change, mean (95% CI) compared with diagnosis | | | | |
| Year-1 | −2.73 (−5.84 to +0.38) | −0.07 (−4.10 to +3.95) | −7.58 (−16.19 to 1.03) | −14.41 (−30.37 to +1.54) |
| Year-2 | −1.89 (−5.24 to +1.45) | −1.36 (−5.29 to +2.57) | −12.81 (−21.62 to −4.00) | −12.43 (−28.25 to +3.39) |
| Year-4 | −2.32 (−6.65 to +2.02) | +2.62 (−2.64 to +7.88) | −12.48 (−23.81 to −1.15) | −9.41 (−31.86 to +13.04) |
| Transport and leisure-time activity, median (Q1-Q3) | | | | |
| Diagnosis | 10.0 (0.0-24.0) | 6.7 (0.0-20.0) | 4.0 (0.0-18.0) | 0.3 (0.0-18.7) |
| Transport and leisure-time activity, absolute change, mean (95% CI) compared with diagnosis | | | | |
| Year-1 | +1.61 (+0.29 to +2.93) | +4.25 (+2.39 to +6.11) | +1.29 (−2.92 to +5.50) | +2.00 (−3.70 to +7.71) |
| Year-2 | +2.28 (+0.76 to +3.80) | +4.02 (+2.39 to +5.66) | −5.24 (−9.22 to −1.27) | +2.46 (−6.09 to +11.01) |
| Year-4 | +2.00 (+0.13 to +3.87) | +6.07 (+3.76 to +8.39) | −1.72 (−6.70 to +3.26) | +0.66 (−8.98 to +10.30) |
| Insufficiently active (< 10 MET-hours/week), % | | | | |
| Diagnosis | 42.7 | 48.2 | 42.9 | 50.0 |
| Year-1 | 35.6 | 38.8 | 43.3 | 46.4 |

<div align="center">(continued on following page)</div>

**TABLE 3.** Distribution of Health Behaviors by Quality of Life Trajectory Group in the Whole Cohort (N = 4,131) (continued)

| Health Behavior | Excellent (n = 2,134; 51.7%) | Very Good (n = 1,312; 31.7%) | Deteriorating (n = 413; 10.0%) | Poor (n = 272; 6.6%) |
|---|---|---|---|---|
| Year-2 | 36.6 | 39.5 | 45.0 | 47.7 |
| Year-4 | 36.4 | 37.6 | 46.3 | 52.1 |
| Smoke behavior among current smokers at diagnosis, % | | | | |
| Persistence or increased use compared with previous visit | n = 339 (16.1%) | n = 260 (20.2%) | n = 107 (26.3%) | n = 96 (35.4%) |
| Year-1 | 55.4 | 61.0 | 63.7 | 67.1 |
| Year-2 | 50.2 | 45.7 | 50.6 | 54.3 |
| Year-4 | 44.9 | 46.6 | 47.6 | 44.9 |
| Alcohol use behavior among daily consumers at diagnosis, % | | | | |
| Persistence or increased use compared with previous visit | n = 281 (13.6%) | n = 173 (13.6%) | n = 53 (13.2%) | n = 42 (16.0%) |
| Year-1 | 88.4 | 85.3 | 83.0 | 82.3 |
| Year-2 | 86.4 | 75.0 | 67.3 | 70.0 |
| Year-4 | 85.4 | 76.0 | 67.6 | 68.2 |

NOTE. Evaluation as to whether weight loss was purposeful cannot be performed. Caution is advised in interpretation of changes over time, especially in smaller groups where mean changes may be driven by extreme values.

Abbreviations: BMI, body mass index; MET, metabolic equivalents of task; PA, physical activity; Q1, quartile 1; Q3, quartile 3; SD, standard deviation.

[a]A weight change as low as 5% of baseline can be considered clinically meaningful.

trajectory group. Factors associated with membership to this group also included younger age, comorbidities, lower income, and endocrine therapy.

Although the majority of patients in our cohort had fairly good QOL trajectories, for two specific patient clusters, the long-term QOL dynamics were worryingly worse. The deteriorating QOL group was most affected by primary treatment, experiencing a dramatic drop from diagnosis to year-1, which never recovered. A sharp deterioration was observed for multiple functions in this segment, particularly physical, social, cognitive, and role function, and symptoms including fatigue and pain. These changes can be dramatic from a patient's perspective, qualifying as moderately-to-very-much worse than before treatment,[53] and are considered of medium-to-large magnitude.[54] Almost all mean scores of the deteriorating trajectory group met validated thresholds of clinical importance, red-flagging functional impairment and severe symptoms that should trigger clinician attention and urge dedicated supportive care.[52]

Previous literature tried to describe postchemotherapy changes in QOL, albeit most of it did not comprehensively explore long-term patterns, only captured population averages, or was focused on specific symptoms.[6,7,14,15] Here, we present several elements of novelty, providing a nuanced description of QOL trajectories 4 years after diagnosis, comprehensively assessing overall and specific QOL metrics, and offering insight into the characteristics of latent subpopulations with persistent deterioration.

Our data add to the knowledge about the relationship of several host factors and behaviors with patients' QOL. Women with obesity and current smokers were most likely to cluster into the deteriorating QOL group, where excess weight increased to more than 60% prevalence at year-4 and smoking persistence was frequent during chemotherapy. Surprisingly, women with deteriorating QOL patterns had high PA levels at diagnosis, and the majority adhered to PA recommendations. Nevertheless, this group seemed to have a decline in total PA participation, including reduced work-related PA (perhaps reflecting physical efforts that patients were not able to maintain) and seemed not to substantially increase their leisure-time exercise including sports or recreational PA (compared, for example, to the very good QOL group).

From a biologic standpoint, studies suggested that QOL deterioration may be mediated by the observed unhealthy behaviors. An interplay was described between higher BMI and reduced exercise exposure with alterations in circulating biomarkers, such as inflammation-axis effectors, immunomodulatory cytokines, metabolic-steroid hormones, and growth factors, which can contribute to symptom deterioration and worse treatment-related side effects.[18,55-58] Similar inflammatory alterations, exacerbated by tissue hypoxia and hormone level and circadian rhythm disruptions, were observed in persistent smokers.[23,24,59-61] Adaptation to less physically demanding tasks, as a consequence of decreased PA levels, may also lead to

progressive deconditioning, a process of decline in cardiorespiratory and muscular functional capacity,[62] which previous literature linked to reduced fitness, limited physical performance, and worsening cancer-related symptoms, such as fatigue.[20,22] Finally, reduction in serum estrogen and higher symptom burden associated with endocrine therapy—another of the factors associated with membership to this trajectory—may have deleterious physiologic consequences on multiple systems and interfere with exercise capacity and tolerance.[62,63]

Whether behavioral changes occurring after diagnosis of BC can influence recurrence and cancer-related outcomes, including QOL, is the subject of vivid research. Lifestyle interventions proved safe, feasible, and effective for several outcomes in women with BC.[18,64-68] For example, exercise training during and after completion of chemotherapy led to improvements in physiologic variables and psychosocial status,[69] with beneficial effects on QOL.[19] Behavioral trials of weight loss in overweight and obese BC survivors showed an impact on QOL that was particularly evident on physical function, vitality, and comorbid conditions, but most benefits tended to diminish over time, a finding that is mostly attributed to recidivism and weight regain during postintervention follow-up.[70-72] Ongoing randomized trials will provide additional PROs data and test whether combined interventions of weight loss (ie, with multiple components of improved diet, PA, and personalized behavioral coaching),[73-75] or smoking cessation programs[64,76] are able to reduce treatment-related symptoms, improve QOL, and affect clinical outcomes of BC survivors.

Our findings also highlight contextual, nonbehavioral factors, such as lower income, as strong determinants of membership to trajectory groups with worse QOL. Previous studies suggested that patients from low social classes usually have prolonged post-treatment recovery time and are often at risk of severely impaired physical and psychosocial health.[77] Contributing factors may include lower purchasing power and limited access to supportive care options requiring out-of-pocket expenditures, or job instability and dissatisfaction leading to poor social and role functioning.[78] A higher socioeconomic class may also afford better opportunities and flexibility to modulate behavioral factors, and facilitate the uptake of a healthier lifestyle.[79] Taken together, these data call for a need to proactively promote and prioritize social work interventions in the clinical setting, targeting patient subgroups with indicators of socioeconomic disadvantage that may recover more slowly and remain disabled after chemotherapy. A better understanding of social determinants of health is all the more important in our cohort of BC survivors, where having universal access to health care does not seem to mitigate the impact of social factors as a driver of disparities in health-related outcomes.

Finally, adjuvant endocrine therapy specifically contributed to membership to the deteriorating QOL group. In our previous CANTO analysis,[80] endocrine therapy acted as a major player determining a similar, persistent detrimental impact on QOL. Analogously, the resolution of many systemic therapy–associated symptoms was delayed among patients receiving endocrine therapy in the Mind Body Study.[63] From a clinical perspective, these findings are particularly relevant. Greater treatment-related symptom burden is among the main reasons for nonadherence and discontinuation of endocrine therapy that ultimately can contribute to poorer clinical outcomes.[81,82] In the context of recently consolidated strategies of endocrine therapy escalation,[83-85] particular attention should be given to specific subgroups, such as younger women, who seem to be at higher risk of QOL deterioration and persistent symptoms.[86]

The strengths of this study include its prospective, longitudinal design, and a large and heterogeneous sample. We analyzed a single, higher-order QOL outcome measure that summarizes multiple scales into a multidimensional response profile, thus avoiding multiple comparisons.[35,38] Specific psychometric properties include robustness against inherent PROs limitations, such as dispositional optimism and response shift.[87-89] A major novelty is the use of GBTM, which avoided summarizing QOL data by fitting a simplistic population mean, and allowing to unmask clinically relevant latent groups.

Among common limitations of longitudinal studies such as CANTO is response attrition particularly at later time points, and the results may be driven by midterm changes. In addition, our models fit CANTO data describing a population of women with early-stage BC who were free of disease at the time of QOL assessments. Second, trajectory groups are not necessarily fixed and may change, as GBTM performs a dynamic grouping that is susceptible to additional follow-up.[45] However, GBTM is particularly robust at accommodating missing outcome data and sensitivity analyses trying to address these points confirmed the robustness of our findings. Caution is advised in interpreting some results such as weight changes, because of difficulty to establish intentionality (eg, of weight loss) and small numbers in certain categories. With only a baseline and year-1 assessment, we could not detail QOL evolution during chemotherapy, although we offer a long-term landscape view revealing variability evidenced only after several years postdiagnosis.

This dynamic portrait of postchemotherapy QOL identifies and characterizes patients at risk of steep, clinically meaningful decline. Some factors that were associated with membership to the deteriorating trajectory were nonmodifiable, such as lower income or endocrine therapy. On the contrary, healthy behaviors were consistently and positively associated with better performing trajectory groups. Weight modulation, PA uptake, and tobacco abstinence are modifiable behaviors and potential tools to combat functional health impairment and symptom exacerbation, mitigating the detrimental impact of chemotherapy. However, behavioral interventions supporting

lifestyle changes may be difficult to implement.[90,91] Personalization is paramount in the current scenario where lifestyle-change programs are not standard of care and cancer is not universally a qualifying diagnosis for third-party reimbursement of behavioral interventions.[65,66,76] To optimize resource utilization, research is increasingly focused on healthy lifestyle-promotion interventions among specific target subpopulations, and on optimal ways to deliver patient-specific behavioral support.[64,66,76] This study offers further insight on screening relevant patient-level factors and identifying at-risk patient clusters suitable for tailored interventions for QOL preservation, including early addressal of behavioral concerns and provision of healthy lifestyle-support programs.

## AFFILIATIONS

[1]Medical Oncology, Gustave Roussy, Villejuif, France

[2]INSERM Unit 981, Molecular Predictors and New Targets in Oncology, Gustave Roussy, University Paris-Saclay, Villejuif, France

[3]Sorbonne Université, INSERM, IPLESP, Paris, France

[4]Université de Paris, ECEVE UMR 1123, INSERM, Paris, France

[5]UNICANCER, Paris, France

[6]Institut Curie, Paris, France

[7]Institut Curie Saint Cloud, Saint Cloud, France

[8]Centre Georges-François Leclerc, Dijon, France

[9]Institut de Cancérologie de Lorraine, Nancy, France

[10]Centre Léon Bérard, Lyon, France

[11]Centre Paul Papin, Angers, France

[12]Centre Oscar Lambret, Lille, France

[13]Centre Francois Baclesse, Caen, France

[14]University of California, Los Angeles, CA

[15]Dana-Farber Cancer Institute, Boston, MA

[16]Memorial Sloan Kettering Cancer Center, New York, NY

[17]Service de Biostatistique et d'Épidémiologie, Oncostat Inserm U1018, Université Paris- Saclay, Equipe labellisée Ligue Contre le Cancer, Gustave Roussy, Villejuif, France

## CORRESPONDING AUTHOR

Ines Vaz-Luis, MD, PhD, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94800 Villejuif, France; e-mail: INES-MARIA.VAZ-DUARTE-LUIS@gustaveroussy.fr.

## PRIOR PRESENTATION

Presented in part at the European Society for Medical Oncology (ESMO) Congress, October 20, 2018 (abstr 1684PD_PR). Portions of this work were also highlighted in the official ESMO Press Release (https://www.esmo.org/newsroom/press-office/physical-exercise-qol-chemotherapy-sports-cancer-dimeglio-vanlemmens).

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.21.00277.

## AUTHOR CONTRIBUTIONS

**Conception and design:** Antonio Di Meglio, Patricia A. Ganz, Ann H. Partridge, Stefan Michiels, Ines Vaz-Luis

**Financial support:** Antonio Di Meglio, Ines Vaz-Luis

**Administrative support:** Sibille Everhard, Anne-Laure Martin

**Provision of study materials or patients:** Barbara Pistilli, Paul H. Cottu, Florence Lerebours, Charles Coutant, Anne Lesur, Olivier Tredan, Patrick Soulie, Laurence Vanlemmens, Florence Joly, Suzette Delaloge, Fabrice André

**Collection and assembly of data:** Sibille Everhard, Anne-Laure Martin

**Data analysis and interpretation:** Antonio Di Meglio, Julie Havas, Arnauld S. Gbenou, Elise Martin, Mayssam El-Mouhebb, Barbara Pistilli, Gwenn Menvielle, Agnes Dumas, Anne-Laure Martin, Paul H. Cottu, Florence Lerebours, Charles Coutant, Anne Lesur, Patrick Soulie, Florence Joly, Suzette Delaloge, Patricia A. Ganz, Fabrice André, Ann H. Partridge, Lee W Jones, Stefan Michiels, Ines Vaz-Luis

**Manuscript writing:** All authors

**Final approval of manuscript:** All authors

**Accountable for all aspects of the work:** All authors

## REFERENCES

1. Allemani C, Weir HK, Carreira H, et al: Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 385:977-1010, 2015

2. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005

3. DeSantis CE, Bray F, Ferlay J, et al: International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 24:1495-1506, 2015

4. Saadatmand S, Bretveld R, Siesling S, et al: Influence of tumour stage at breast cancer detection on survival in modern times: Population based study in 173 797 patients. BMJ 351:h4901, 2015

5. SEER Cancer Statistics Review 1975-2006-Previous Version—SEER Cancer Statistics. https://seer.cancer.gov/archive/csr/1975_2006/

6. Sheng JY, Visvanathan K, Thorner E, et al: Breast cancer survivorship care beyond local and systemic therapy. Breast 48:S103-S109, 2019

7. Brauer ER, Ganz PA: Health burden in cancer survivors: Below the tip of the iceberg. Nat Rev Clin Oncol 16:467-468, 2019

8. Howard-Anderson J, Ganz PA, Bower JE, et al: Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review. J Natl Cancer Inst 104:386-405, 2012

9.  Ahles TA, Saykin AJ, McDonald BC, et al: Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. J Clin Oncol 28:4434-4440, 2010

10. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in breast cancer survivors: Occurrence, correlates, and impact on quality of life. J Clin Oncol 18:743-753, 2000

11. Bandos H, Melnikow J, Rivera DR, et al: Long-term peripheral neuropathy in breast cancer patients treated with adjuvant chemotherapy: NRG oncology/NSABP B-30. J Natl Cancer Inst 110:djx162, 2017

12. Hassett MJ, O'Malley AJ, Pakes JR, et al: Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 98:1108-1117, 2006

13. Dumas A, Vaz Luis I, Bovagnet T, et al: Impact of breast cancer treatment on employment: Results of a multicenter prospective cohort study (CANTO). J Clin Oncol 38:734-743, 2020

14. Andrykowski MA, Donovan KA, Laronga C, et al: Prevalence, predictors, and characteristics of off-treatment fatigue in breast cancer survivors. Cancer 116: 5740-5748, 2010

15. Bower JE, Wiley J, Petersen L, et al: Fatigue after breast cancer treatment: Biobehavioral predictors of fatigue trajectories. Heal Psychol 37:1025-1034, 2018

16. Bower JE, Ganz PA, Desmond KA, et al: Fatigue in long-term breast carcinoma survivors. Cancer 106:751-758, 2006

17. Di Meglio A, Michiels S, Jones LW, et al: Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study. Breast 52:23-32, 2020

18. Chlebowski RT, Reeves MM: Weight loss randomized intervention trials in female cancer survivors. J Clin Oncol 34:4238-4248, 2016

19. Mishra SI, Scherer RW, Snyder C, et al: Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012:CD008465, 2012

20. Mishra SI, Scherer RW, Geigle PM, et al: Exercise interventions on health-related quality of life for cancer survivors. Cochrane Database Syst Rev 2012: CD007566, 2012

21. Kroenke CH, Chen WY, Rosner B, et al: Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol 23:1370-1378, 2005

22. Irwin ML, Smith AW, McTiernan A, et al: Influence of pre- and postdiagnosis physical activity on mortality in breast cancer survivors: The health, eating, activity, and lifestyle study. J Clin Oncol 26:3958-3964, 2008

23. Peppone LJ, Mustian KM, Morrow GR, et al: The effect of cigarette smoking on cancer treatment–related side effects. Oncologist 16:1784-1792, 2011

24. Warren GW, Sobus S, Gritz ER: The biological and clinical effects of smoking by patients with cancer and strategies to implement evidence-based tobacco cessation support. Lancet Oncol 15:e568-e580, 2014

25. Zhan M, Flaws JA, Gallicchio L, et al: Profiles of tamoxifen-related side effects by race and smoking status in women with breast cancer. Cancer Detect Prev 31: 384-390, 2007

26. Land SR, Cronin WM, Wickerham DL, et al: Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project P-1 breast cancer prevention trial. Cancer Prev Res 4:1393-1400, 2011

27. Peters EN, Torres E, Toll BA, et al: Tobacco assessment in actively accruing national cancer Institute cooperative group program clinical trials. J Clin Oncol 30: 2869-2875, 2012

28. Ganz PA: Host factors, behaviors, and clinical trials: Opportunities and challenges. J Clin Oncol 30:2817-2819, 2012

29. Goodwin SJ, McCarthy CM, Pusic AL, et al: Complications in smokers after postmastectomy tissue expander/implant breast reconstruction. Ann Plast Surg 55: 16-20, 2005

30. Jang S, Prizment A, Haddad T, et al: Smoking and quality of life among female survivors of breast, colorectal and endometrial cancers in a prospective cohort study. J Cancer Surviv 5:115-122, 2011

31. Parada H, Bradshaw PT, Steck SE, et al: Postdiagnosis changes in cigarette smoking and survival following breast cancer. JNCI Cancer Spectr 1:pkx001, 2017

32. Passarelli MN, Newcomb PA, Hampton JM, et al: Cigarette smoking before and after breast cancer diagnosis: Mortality from breast cancer and smoking-related diseases. J Clin Oncol 34:1315-1322, 2016

33. Balaam S, Bailey TG, Anderson D, et al: Alcohol and breast cancer: Results from the women's wellness after cancer program randomized controlled trial. Cancer Nurs 45:87-95, 2022

34. Tipples K, Robinson A: Optimal management of cancer treatment-induced bone loss: Considerations for elderly patients. Drugs Aging 28:867-883, 2011

35. Husson O, de Rooij BH, Kieffer J, et al: The EORTC QLQ-C30 summary score as prognostic factor for survival of patients with cancer in the "real-world": Results from the population- based PROFILES registry. Oncologist 25:e722-e732, 2020

36. Vaz-Luis I, Cottu P, Mesleard C, et al: UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO). ESMO Open 4:e000562, 2019

37. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993

38. Giesinger JM, Kieffer JM, Fayers PM, et al: Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol 69:79-88, 2016

39. Fayers P, Aaronson NK, Bjordal K, et al: EORTC QLQ-C30 Scoring Manual. Brussels, Belgium, European Organisation for Research and Treatment of Cancer, 2001

40. Sprangers MA, Groenvold M, Arraras JI, et al: The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J Clin Oncol 14:2756-2768, 1996

41. QuestionnaireslEORTC—Quality of Life. https://qol.eortc.org/questionnaires/

42. Data and Statistics. 2019. http://www.euro.who.int/en/health-topics/noncommunicable-diseases/obesity/data-and-statistics

43. Global Physical Activity Questionnaire Analysis Guide GPAQ Analysis Guide Global Physical Activity Questionnaire (GPAQ) Analysis Guide. http://www.who.int/chp/steps/GPAQ/en/index.html

44. Nagin DS, Odgers CL: Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol 6:109-138, 2010

45. Nagin DS, Jones BL, Passos VL, et al: Group-based multi-trajectory modeling. Stat Methods Med Res 27:2015-2023, 2018

46. Nagin DS: Group-Based Modeling of Development. Cambridge, MA, Harvard University Press, 2005

47. Choi CWJ, Stone RA, Kim KH, et al: Group-based trajectory modeling of caregiver psychological distress over time. Ann Behav Med 44:73-84, 2012

48. Nagin DS, Odgers CL: Group-based trajectory modeling (nearly) two decades later. J Quant Criminol 26:445-453, 2010

49. van Buuren S, Groothuis-Oudshoorn K: mice: Multivariate imputation by chained equations in R. J Stat Softw 45:1-67, 2011

50. Rubin DB, Wiley J, York N, et al: Multiple Imputation for Nonresponse in Surveys. Hoboken, NJ, John Wiley & Sons Inc, 1987

51. Haviland AM, Jones BL, Nagin DS: Group-based trajectory modeling extended to account for nonrandom participant attrition. Sociologic Methods Res 40: 367-390, 2011

52. Giesinger JM, Loth FLC, Aaronson NK, et al: Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J Clin Epidemiol 118:1-8, 2020

53. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998

54. Cocks K, King MT, Velikova G, et al: Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 29:89-96, 2011

55. Jones LW, Eves ND, Scott JM: Bench-to-bedside approaches for personalized exercise therapy in cancer. Am Soc Clin Oncol Ed Book 37:684-694, 2017

56. Ballard-Barbash R, Hunsberger S, Alciati MH, et al: Physical activity, weight control, and breast cancer risk and survival: Clinical trial rationale and design considerations. J Natl Cancer Inst 101:630-643, 2009

57. Goodwin PJ, Ambrosone CB, Hong C-C: Modifiable lifestyle factors and breast cancer outcomes: Current controversies and research recommendations, in Advances in Experimental Medicine and Biology. New York, NY, Springer New York LLC, 2015, pp 177-192

58. Betof AS, Dewhirst MW, Jones LW: Effects and potential mechanisms of exercise training on cancer progression: A translational perspective. Brain Behav Immun 30:S75-S87, 2013

59. Ferson M, Edwards A, Lind A, et al: Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer 23: 603-609, 1979

60. Tartter PI, Steinberg B, Barron DM, et al: The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg 122:1264-1268, 1987

61. Browman GP, Wong G, Hodson I, et al: Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med 328:159-163, 1993

62. Jones LW, Eves ND, Haykowsky M, et al: Exercise intolerance in cancer and the role of exercise therapy to reverse dysfunction. Lancet Oncol 10:598-605, 2009

63. Ganz PA, Petersen L, Bower JE, et al: Impact of adjuvant endocrine therapy on quality of life and symptoms: Observational data over 12 months from the mind-body study. J Clin Oncol 34:816-824, 2016

64. LoConte NK, Gershenwald JE, Thomson CA, et al: Lifestyle modifications and policy Implications for primary and secondary cancer prevention: Diet, exercise, sun safety, and alcohol reduction. Am Soc Clin Oncol Ed Book 38:88-100, 2018

65. Demark-Wahnefried W, Schmitz KH, Alfano CM, et al: Weight management and physical activity throughout the cancer care continuum. CA Cancer J Clin 68: 64-89, 2018

66. Iyengar NM, Jones LW: Development of exercise as interception therapy for cancer: A review. JAMA Oncol 5:1620-1627, 2019

67. Gritz ER, Fingeret MC, Vidrine DJ, et al: Successes and failures of the teachable moment: Smoking cessation in cancer patients. Cancer 106:17-27, 2006

68. Klosky JL, Tyc VL, Garces-Webb DM, et al: Emerging issues in smoking among adolescent and adult cancer survivors. Cancer 110:2408-2419, 2007

69. Speck RM, Courneya KS, Mâsse LC, et al: An update of controlled physical activity trials in cancer survivors: A systematic review and meta-analysis. J Cancer Surviv 4:87-100, 2010

70. Sedjo RL, Flatt SW, Byers T, et al: Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors. Support Care Cancer 24:3285-3293, 2016

71. Demark-Wahnefried W, Colditz GA, Rock CL, et al: Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors. Breast Cancer Res Treat 154:329-337, 2015

72. Kenzik KM, Demark-Wahnefried W, Ganz PA, et al: Changes in body mass index and physical activity predict changes in vitality during a weight loss trial in breast cancer survivors. Ann Behav Med 52:999-1009, 2018

73. Ligibel JA, Barry WT, Alfano C, et al: Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): Study design. NPJ Breast Cancer 3:37, 2017

74. Rack B, Andergassen U, Neugebauer J, et al: The German SUCCESS C study—The first European lifestyle study on breast cancer. Breast Care 5:395-400, 2010

75. Di Meglio A, Martin E, Crane TE, et al: A phase III randomized trial of weight loss to reduce cancer-related fatigue among overweight and obese breast cancer patients: MEDEA study design. Trials 23:193, 2022

76. Land SR, Toll BA, Moinpour CM, et al: Research priorities, measures, and recommendations for assessment of tobacco use in clinical cancer research. Clin Cancer Res 22:1907-1913, 2016

77. Ell K, Xie B, Wells A, et al: Economic stress among low-income women with cancer: Effects on quality of life. Cancer 112:616-625, 2008

78. Graells-Sans A, Serral G, Puigpinós-Riera R: Social inequalities in quality of life in a cohort of women diagnosed with breast cancer in Barcelona (DAMA cohort). Cancer Epidemiol 54:38-47, 2018

79. Khadanga S, Lakoski SG, Hart V, et al: Partnership status and socioeconomic factors in relation to health behavior changes after a diagnosis of ductal carcinoma in situ. Cancer Epidemiol Biomarkers Prev 25:76-82, 2016

80. Ferreira ARR, Di Meglio A, Pistilli B, et al: Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: A prospective patient-reported outcomes analysis. Ann Oncol 30:1784-1795, 2019

81. Chirgwin JH, Giobbie-Hurder A, Coates AS, et al: Treatment adherence and its impact on disease-free survival in the breast international group 1-98 trial of tamoxifen and letrozole, alone and in sequence. J Clin Oncol 34:2452-2459, 2016

82. Pistilli B, Paci A, Ferreira AR, et al: Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk. J Clin Oncol 38:2762-2772, 2020

83. Ribi K, Luo W, Bernhard J, et al: Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: Patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 34:1601-1610, 2016

84. Davies C, Pan H, Godwin J, et al: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805-816, 2013

85. Gray RG, Rea D, Handley K, et al: aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31, 2013 (abstr 5)

86. Di Meglio A, Havas J, Soldato D, et al: Development and validation of a predictive model of severe fatigue after breast cancer diagnosis: Toward a personalized framework in survivorship care. J Clin Oncol 40:1111-1123, 2022

87. Phillips R, Gandhi M, Cheung YB, et al: Summary scores captured changes in subjects' QoL as measured by the multiple scales of the EORTC QLQ-C30. J Clin Epidemiol 68:895-902, 2015

88. Sprangers MAG: Disregarding clinical trial-based patient-reported outcomes is unwarranted: Five advances to substantiate the scientific stringency of quality-of-life measurement. Acta Oncol (Madr) 49:155-163, 2010

89. Sprangers MAG, Schwartz CE: Integrating response shift into health-related quality of life research: A theoretical model. Soc Sci Med 48:1507-1515, 1999

90. Phillips SM, Alfano CM, Perna FM, et al: Accelerating translation of physical activity and cancer survivorship research into practice: Recommendations for a more integrated and collaborative approach. Cancer Epidemiol Biomarkers Prev 23:687-699, 2014

91. Stull VB, Snyder DC, Demark-Wahnefried W: Lifestyle interventions in cancer survivors: Designing programs that meet the needs of this vulnerable and growing population. J Nutr 137:243S-248S, 2007 (suppl 1)

■ ■ ■

**ASCO** | AMERICAN SOCIETY OF CLINICAL ONCOLOGY

**KNOWLEDGE CONQUERS CANCER**

ASCO offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide.

View upcoming Meetings and Symposia at **meetings.asco.org**.

## AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

**Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy**

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

**Barbara Pistilli**
**Consulting or Advisory Role:** Puma Biotechnology, Pierre Fabre, Novartis, Myriad Genetics, AstraZeneca, Daiichi Sankyo/UCB Japan
**Research Funding:** Pfizer (Inst), Puma Biotechnology (Inst), Merus (Inst), Daiichi-Sankyo (Inst)
**Travel, Accommodations, Expenses:** Pfizer, AstraZeneca, MSD Oncology, Novartis, Pierre Fabre

**Paul H. Cottu**
**Honoraria:** Pfizer, Novartis (Inst), Roche, NanoString Technologies (Inst), Lilly
**Consulting or Advisory Role:** Pfizer, Lilly
**Research Funding:** Pfizer (Inst)
**Travel, Accommodations, Expenses:** Roche, Pfizer

**Florence Lerebours**
**Consulting or Advisory Role:** AstraZeneca, Eisai, Lilly, Pierre Fabre, Roche, Pfizer, Novartis, Seattle Genetics
**Travel, Accommodations, Expenses:** Novartis, Pfizer, Roche, Eisai, Mundipharma

**Charles Coutant**
**Travel, Accommodations, Expenses:** Roche, MSD, AstraZeneca, Pfizer, Seattle Genetics, Exact Sciences

**Olivier Tredan**
**Consulting or Advisory Role:** Roche, Pfizer, Lilly, AstraZeneca, MSD Oncology, Daiichi Sankyo Europe GmbH, Eisai Europe, Sandoz-Novartis, Seattle Genetics, Pierre Fabre, Gilead Sciences
**Research Funding:** Roche (Inst), Bristol Myers Squibb (Inst), MSD Oncology (Inst), AstraZeneca (Inst), Novartis (Inst), Bayer (Inst)
**Travel, Accommodations, Expenses:** Roche, Novartis, Pfizer, Lilly, AstraZeneca, MSD Oncology

**Patrick Soulie**
**Travel, Accommodations, Expenses:** Pfizer, PharmaMar, Ipsen

**Florence Joly**
**Consulting or Advisory Role:** AstraZeneca, Janssen, Ipsen, Pfizer, MSD Oncology, Bristol Myers Squibb, GlaxoSmithKline, Astellas Pharma, Clovis Oncology, Amgen, Seattle Genetics, Bayer
**Travel, Accommodations, Expenses:** Janssen, AstraZeneca, Ipsen, GlaxoSmithKline, BMS

**Suzette Delaloge**
**Consulting or Advisory Role:** AstraZeneca (Inst), Sanfi (Inst), Besins Healthcare (Inst), Rappta Therapeutics (Inst)
**Research Funding:** AstraZeneca (Inst), Pfizer (Inst), Roche/Genentech (Inst), Puma Biotechnology (Inst), Lilly (Inst), Novartis (Inst), Sanofi (Inst), Exact Sciences (Inst), Bristol Myers Squibb (Inst)
**Travel, Accommodations, Expenses:** Pfizer, AstraZeneca, Novartis (Inst)

**Patricia A. Ganz**
**Leadership:** Intrinsic LifeSciences (I)
**Stock and Other Ownership Interests:** Xenon Pharma (I), Intrinsic LifeSciences (I), Silarus Therapeutics (I), Teva, Novartis, Merck, Johnson & Johnson, Pfizer, GlaxoSmithKline, Abbott Laboratories
**Consulting or Advisory Role:** InformedDNA, Vifor Pharma (I), Ambys Medicines (I), Global Blood Therapeutics (I), GlaxoSmithKline (I), Ionis Pharmaceuticals (I), Akebia Therapeutics (I), Protagonist Therapeutics (I), Regeneron (I), Sierra Oncology (I), Rockwell Medical Technologies Inc (I), Astellas Pharma (I), Gossamer Bio (I), American Regent (I), Disc Medicine (I), Blue Note Therapeutics, Grail
**Research Funding:** Blue Note Therapeutics (Inst)
**Patents, Royalties, Other Intellectual Property:** related to iron metabolism and the anemia of chronic disease (I), Up-to-Date royalties for section editor on survivorship
**Travel, Accommodations, Expenses:** Intrinsic LifeSciences (I)

**Fabrice André**
**Stock and Other Ownership Interests:** Pegacsy
**Research Funding:** AstraZeneca (Inst), Novartis (Inst), Pfizer (Inst), Lilly (Inst), Roche (Inst), Daiichi (Inst)
**Travel, Accommodations, Expenses:** Novartis, Roche, GlaxoSmithKline, AstraZeneca

**Ann H. Partridge**
**Patents, Royalties, Other Intellectual Property:** I receive small royalty payments for coauthoring the breast cancer survivorship section of UpToDate
**Open Payments Link:** https://openpaymentsdata.cms.gov/physician/835197

**Lee W. Jones**
**Stock and Other Ownership Interests:** Pacylex

**Stefan Michiels**
**Consulting or Advisory Role:** IDDI, Sensorion, Biophytis, Servier, Yuhan, Amaris Consulting, Roche

**Ines Vaz-Luis**
**Honoraria:** AstraZeneca (Inst), Amgen (Inst), Pfizer (Inst)

No other potential conflicts of interest were reported.